Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)

Summary Neoadjuvant therapy (NAT) in breast cancer is administered to downstage the tumor, de-escalate surgery, and provide prognostic information that can be used to tailor subsequent adjuvant therapy. In this respect, the pathological evaluation of both pre-NAT biopsies and post-NAT surgical specimens is crucial to precisely assess the treatment response. With the increasing possibilities of NAT protocols and the rising number of eligible patients, it has become extremely important to standardize the pathological response assessment. Here, we provide an update on the recommendations of the Italian Group for the Study of Breast Pathology - the Italian Society of Pathology (GIPaM-SIAPeC) for the analysis of breast cancer samples before and after NAT.

[1]  G. Botti,et al.  Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement , 2021, Tumori.

[2]  L. Esserman,et al.  Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients , 2021, The Lancet. Oncology.

[3]  M. Rajagopal,et al.  Health-Related Suffering and Palliative Care in Breast Cancer , 2021, Current Breast Cancer Reports.

[4]  C. Criscitiello,et al.  Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. , 2021, Histology and histopathology.

[5]  G. Viale,et al.  Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study , 2021, Frontiers in Oncology.

[6]  M. Golatta,et al.  Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries? , 2021, Breast Cancer Research and Treatment.

[7]  S. Carda,et al.  Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies. , 2021, Anti-cancer agents in medicinal chemistry.

[8]  G. Viale,et al.  Pathology after neoadjuvant treatment – How to assess residual disease , 2021, Breast.

[9]  A. Kwong,et al.  Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review , 2021, Breast Cancer Research and Treatment.

[10]  M. Fassan,et al.  The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization , 2021, Diagnostics.

[11]  M. Somerfield,et al.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Yee,et al.  Recent advances in neoadjuvant therapy for breast cancer , 2021, Faculty Reviews.

[13]  M. Invernizzi,et al.  Editorial: Quality of Life in Breast Cancer Patients and Survivors , 2020, Frontiers in Oncology.

[14]  C. Tinterri,et al.  Pre-analytics, a national survey of Senonetwork Italia breast centers: Much still to do ahead. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  J. Graham,et al.  Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines , 2020, Breast Cancer Research.

[16]  S. Rubinelli,et al.  Breast Cancer Survivorship, Quality of Life, and Late Toxicities , 2020, Frontiers in Oncology.

[17]  F. Reyal,et al.  Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis , 2020, PloS one.

[18]  G. Bills,et al.  Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB) , 2020, Breast Cancer Research and Treatment.

[19]  G. Cserni.  Histological type and typing of breast carcinomas and the WHO classification changes over time , 2020, Pathologica.

[20]  A. Sapino,et al.  Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer , 2020, Frontiers in Oncology.

[21]  F. Zerwes,et al.  Role of Axillary Surgery After Neoadjuvant Chemotherapy , 2020, JCO global oncology.

[22]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Caudle,et al.  Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques , 2019, Annals of Surgical Oncology.

[24]  E. Provenzano,et al.  Axillary Surgery Following Neoadjuvant Chemotherapy - Multidisciplinary Guidance From the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radio , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  M. Invernizzi,et al.  Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management. , 2019, Breast.

[26]  F. Frusone,et al.  Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation? , 2019, The breast journal.

[27]  I. Wapnir,et al.  Current Strategies for the Management of Locoregional Breast Cancer Recurrence. , 2019, Oncology.

[28]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Invernizzi,et al.  Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up , 2018, BMC Cancer.

[30]  R. Bartsch,et al.  Current concepts and future directions in neoadjuvant chemotherapy of breast cancer , 2018, memo - Magazine of European Medical Oncology.

[31]  M. Morrow,et al.  Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? , 2018, Annals of Surgical Oncology.

[32]  A. Vincent-Salomon,et al.  Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma , 2018, Breast Cancer Research and Treatment.

[33]  H. Yamashiro,et al.  Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer , 2017, Breast Cancer.

[34]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[35]  E. Rutgers,et al.  European Breast Cancer Conference manifesto on breast centres/units. , 2017, European journal of cancer.

[36]  J. Ahn,et al.  Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period , 2016, Journal of pathology and translational medicine.

[37]  H. Kuerer,et al.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Chong Geng,et al.  The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis , 2016, PloS one.

[39]  F. Penault-Llorca,et al.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer , 2016, Nature Reviews Clinical Oncology.

[40]  G. Sergi,et al.  Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[41]  S. Pinder,et al.  Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches , 2015, Histopathology.

[42]  L. Esserman,et al.  Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  C. Geyer,et al.  Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer , 2015, Annals of Surgical Oncology.

[44]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Shu Zheng,et al.  Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Clinically Node-Positive Breast Cancer after Neoadjuvant Chemotherapy: A Meta-Analysis , 2014, PloS one.

[46]  M. Morrow,et al.  The Extent of Extracapsular Extension May Influence the Need for Axillary Lymph Node Dissection in Patients with T1–T2 Breast Cancer , 2014, Annals of Surgical Oncology.

[47]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  G. Viale.  Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. , 2013, Breast.

[49]  G. Fuhrman,et al.  Neoadjuvant chemotherapy in the treatment of breast cancer. , 2013, The Surgical clinics of North America.

[50]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[51]  S. Lester,et al.  Manual of Surgical Pathology , 2005 .

[52]  A. Di Leone,et al.  Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. , 2018, Annali italiani di chirurgia.

[53]  Gianni Bussolati,et al.  The pre-analytical phase in surgical pathology. , 2015, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.